GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » ROCE %

American Oncology Network (American Oncology Network) ROCE % : -41.38% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. American Oncology Network's annualized ROCE % for the quarter that ended in Mar. 2024 was -41.38%.


American Oncology Network ROCE % Historical Data

The historical data trend for American Oncology Network's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network ROCE % Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROCE %
- 1.38 3.82 -28.71

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial 5.93 0.07 -48.34 -37.74 -41.38

American Oncology Network ROCE % Calculation

American Oncology Network's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-56.09/( ( (326.228 - 140.938) + (374.453 - 169.045) )/ 2 )
=-56.09/( (185.29+205.408)/ 2 )
=-56.09/195.349
=-28.71 %

American Oncology Network's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-81.412/( ( (374.453 - 169.045) + (421.921 - 233.829) )/ 2 )
=-81.412/( ( 205.408 + 188.092 )/ 2 )
=-81.412/196.75
=-41.38 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oncology Network  (OTCPK:AONCW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


American Oncology Network ROCE % Related Terms

Thank you for viewing the detailed overview of American Oncology Network's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.